JPWO2021020845A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021020845A5 JPWO2021020845A5 JP2022504629A JP2022504629A JPWO2021020845A5 JP WO2021020845 A5 JPWO2021020845 A5 JP WO2021020845A5 JP 2022504629 A JP2022504629 A JP 2022504629A JP 2022504629 A JP2022504629 A JP 2022504629A JP WO2021020845 A5 JPWO2021020845 A5 JP WO2021020845A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- amino acid
- seq
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025145010A JP2026004296A (ja) | 2019-07-26 | 2025-09-02 | 抗ｅｇｆｒ／抗４－１ｂｂ二重特異性抗体及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962878977P | 2019-07-26 | 2019-07-26 | |
| US62/878,977 | 2019-07-26 | ||
| PCT/KR2020/009870 WO2021020845A1 (en) | 2019-07-26 | 2020-07-27 | Anti-egfr/anti-4-1bb bispecific antibody and use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025145010A Division JP2026004296A (ja) | 2019-07-26 | 2025-09-02 | 抗ｅｇｆｒ／抗４－１ｂｂ二重特異性抗体及びその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022542670A JP2022542670A (ja) | 2022-10-06 |
| JP2022542670A5 JP2022542670A5 (https=) | 2023-08-03 |
| JPWO2021020845A5 true JPWO2021020845A5 (https=) | 2023-08-03 |
| JP7738545B2 JP7738545B2 (ja) | 2025-09-12 |
Family
ID=74189704
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022504629A Active JP7738545B2 (ja) | 2019-07-26 | 2020-07-27 | 抗ｅｇｆｒ／抗４－１ｂｂ二重特異性抗体及びその使用 |
| JP2025145010A Pending JP2026004296A (ja) | 2019-07-26 | 2025-09-02 | 抗ｅｇｆｒ／抗４－１ｂｂ二重特異性抗体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025145010A Pending JP2026004296A (ja) | 2019-07-26 | 2025-09-02 | 抗ｅｇｆｒ／抗４－１ｂｂ二重特異性抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12168690B2 (https=) |
| EP (1) | EP4004053A4 (https=) |
| JP (2) | JP7738545B2 (https=) |
| KR (1) | KR20220038767A (https=) |
| CN (2) | CN118221825A (https=) |
| AU (1) | AU2020320349A1 (https=) |
| BR (1) | BR112022001329A2 (https=) |
| CA (1) | CA3147420A1 (https=) |
| MX (1) | MX2022001027A (https=) |
| WO (1) | WO2021020845A1 (https=) |
| ZA (1) | ZA202200905B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20211147A1 (es) | 2019-08-12 | 2021-06-28 | I Mab Biopharma Us Ltd | Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso |
| EP4434548A1 (en) | 2021-11-15 | 2024-09-25 | Systimmune, Inc. | Bispecific antibody-camptothecin drug conjugate and pharmaceutical use thereof |
| US20250320309A1 (en) * | 2021-11-25 | 2025-10-16 | Shenghe (China) Biopharmaceutical Co., Ltd. | Bispecific antigen binding protein |
| JP2025512915A (ja) * | 2022-04-07 | 2025-04-22 | ユハン コーポレーション | Ｈｅｒ２の発現レベルが低いがんを治療又は予防するための薬学的組成物 |
| JP2025542406A (ja) * | 2022-12-30 | 2025-12-25 | アブクロン・インコーポレイテッド | Ｃｄ１３７に特異的に結合するアフィボディ及びその用途 |
| KR20240164748A (ko) * | 2023-05-12 | 2024-11-20 | 앱클론(주) | 항체 또는 그의 항원 결합 단편, 및 어피바디를 포함하는 이중 항원 표적 단백질 복합체 |
| KR102927129B1 (ko) | 2025-03-18 | 2026-02-11 | 이트너스 주식회사 | 임직원 공간 산정을 위한 사무 및 부대 시설 면적 계산 솔루션 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2185770T3 (es) * | 1995-04-08 | 2003-05-01 | Lg Chemical Ltd | Anticuerpo monoclonal especifico para 4-1bb humano y linea celular que lo produce. |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| AU2006211037B2 (en) | 2005-02-07 | 2012-05-24 | Roche Glycart Ag | Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof |
| SI2073842T1 (sl) * | 2006-09-10 | 2015-05-29 | Glycotope Gmbh | Uporaba človeških celic izvirajočih iz mieloične levkemije za izražanje protiteles |
| DK2699598T3 (en) * | 2011-04-19 | 2019-04-23 | Pfizer | COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER |
| JP6539275B2 (ja) * | 2013-08-16 | 2019-07-03 | メモリアル スローン ケタリング キャンサー センター | 選択的ｇｒｐ９４阻害剤およびその使用 |
| SG11201704741PA (en) * | 2014-12-22 | 2017-07-28 | Systimmune Inc | Bispecific tetravalent antibodies and methods of makiing and using thereof |
| EP3356401B1 (en) | 2015-09-30 | 2020-06-24 | IGM Biosciences, Inc. | Binding molecules with modified j-chain |
| FI3436048T3 (fi) | 2016-03-31 | 2025-09-15 | Biontech Us Inc | Neoantigeeneja ja niiden käyttömenetelmiä |
| AU2017252233A1 (en) * | 2016-04-22 | 2018-11-15 | Alligator Bioscience Ab | Novel bispecific polypeptides against CD137 |
| CN118267470A (zh) * | 2017-04-13 | 2024-07-02 | 赛罗帕私人有限公司 | 抗SIRPα抗体 |
| SG11202000503QA (en) * | 2017-07-20 | 2020-02-27 | Aptevo Res & Development Llc | Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods |
| WO2019129644A1 (en) * | 2017-12-28 | 2019-07-04 | Julius-Maximilians-Universität Würzburg | TUMOR NECROSIS FACTOR (TNF) RECEPTOR SUPERFAMILY (TNFRSF) RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FcγR-INDEPENDENT AGONISTIC ACTIVITY (TNFRSF RECEPTOR-ACTIVATING ANTIBODY FUSION PROTEINS WITH FCγR-INDEPENDENT AGONISTIC ACTIVITY; TRAAFFIAA) |
| CN119798453A (zh) * | 2018-11-13 | 2025-04-11 | Jn生物科学有限责任公司 | 激活免疫细胞的双特异性抗体 |
| CN113286825B (zh) * | 2018-11-30 | 2024-06-18 | 爱必乐生物公司 | 抗pd-l1/抗4-1bb双特异性抗体及其用途 |
| PE20211147A1 (es) * | 2019-08-12 | 2021-06-28 | I Mab Biopharma Us Ltd | Anticuerpos anti-claudina 18.2 y anti-4-1bb biespecificos y su uso |
| CA3169943A1 (en) * | 2020-02-28 | 2021-09-02 | Shanghai Henlius Biotech, Inc. | Anti-cd137 constructs, multispecific antibody and uses thereof |
-
2020
- 2020-07-27 US US16/939,472 patent/US12168690B2/en active Active
- 2020-07-27 CN CN202410360186.5A patent/CN118221825A/zh active Pending
- 2020-07-27 BR BR112022001329A patent/BR112022001329A2/pt unknown
- 2020-07-27 WO PCT/KR2020/009870 patent/WO2021020845A1/en not_active Ceased
- 2020-07-27 JP JP2022504629A patent/JP7738545B2/ja active Active
- 2020-07-27 EP EP20848658.9A patent/EP4004053A4/en active Pending
- 2020-07-27 CA CA3147420A patent/CA3147420A1/en active Pending
- 2020-07-27 MX MX2022001027A patent/MX2022001027A/es unknown
- 2020-07-27 CN CN202080053851.6A patent/CN114450306B/zh active Active
- 2020-07-27 KR KR1020227006641A patent/KR20220038767A/ko active Pending
- 2020-07-27 AU AU2020320349A patent/AU2020320349A1/en active Pending
-
2022
- 2022-01-19 ZA ZA2022/00905A patent/ZA202200905B/en unknown
-
2024
- 2024-11-04 US US18/935,875 patent/US20250066487A1/en active Pending
-
2025
- 2025-09-02 JP JP2025145010A patent/JP2026004296A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2376316C2 (ru) | Человеческие антитела против человеческого 4-1вв (cd137) | |
| JP2021531254A5 (https=) | ||
| JP5047996B2 (ja) | 糸球体腎炎および他の炎症性疾患の治療のための組成物および方法 | |
| JP2018527919A5 (https=) | ||
| JP2019535763A5 (https=) | ||
| JP2024056817A5 (https=) | ||
| JP2020505919A5 (https=) | ||
| JP2024016024A5 (https=) | ||
| JPWO2020059847A5 (https=) | ||
| JP2017507131A5 (https=) | ||
| JPWO2020014460A5 (https=) | ||
| JP2020502233A5 (https=) | ||
| JP2021511387A5 (https=) | ||
| JPWO2021020845A5 (https=) | ||
| JPWO2022094299A5 (https=) | ||
| JPWO2021020846A5 (https=) | ||
| JPWO2021007260A5 (https=) | ||
| JP2021521201A5 (https=) | ||
| JPWO2020234399A5 (https=) | ||
| JPWO2022114163A5 (https=) | ||
| JPWO2021068841A5 (https=) | ||
| RU2022101086A (ru) | Биспецифическое антитело анти-HER2/анти-4-1BB и его применение | |
| RU2022101057A (ru) | Биспецифическое антитело анти-egfr/анти-4-1вв и его применение | |
| RU2021119613A (ru) | Гуманизированное антитело против pd-1 и его применение | |
| NZ783106B2 (en) | ANTI-EphA4 ANTIBODY |